Challenges and Opportunities in IBD Clinical Trial Design

The Magic of Randomization versus the Myth of Real-World Evidence

(2020) Rory Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis

(2020) Parambir S. Dulai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Challenges and opportunities for IBD drug development: from early stage to regulatory approval

(2020) Silvio Danese et al.   GUT

Improving Clinical Trial Efficiency in Gastroenterology

(2019) Christopher Ma et al.   GASTROENTEROLOGY

Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy

(2019) Jerome C. Martin et al.   CELL

Competition for Clinical Trials in Inflammatory Bowel Diseases

(2019) M. Scott Harris et al.   GASTROENTEROLOGY

Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa

(2018) Ryo Ozaki et al.   Journal of Crohns & Colitis

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

(2018) Yukihide Momozawa et al.   Nature Communications

Efficient Early Drug Development for Ulcerative Colitis

(2016) Reena Khanna et al.   GASTROENTEROLOGY

Genetics and phenotypes in inflammatory bowel disease

(2016) Joana Torres et al.   LANCET

Adaptive trial designs: a review of barriers and opportunities

(2012) John A Kairalla et al.   Trials